SBIR-STTR Award

A Potential Human Toxicity Assay Using an Expressed Gene
Award last edited on: 5/29/09

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$1,154,466
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Michael E Boerrigter

Company Information

Leven Inc

1551 Jennings Mill Road Suite 2600-B
Bogart, GA 30622
   (706) 613-0196
   N/A
   www.leveninc.com
Location: Single
Congr. District: 10
County: Oconee

Phase I

Contract Number: 1R43CA093242-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2001
Phase I Amount
$156,676
Any mutagenesis assay aimed at elucidating the factors leading to an increased incidence of cancer and purporting to play a relevant role in cancer risk assessment should preferably be applicable to several species, i.e. mouse, rat and human. The existence of a cellular pathway with gene(s) that have been evolutionarily conserved from nematodes to man provide the potential to determine mutant frequencies in virtually any organ of any vertebrate species. All parts for the development of an eukaryotic mutagenesis assay based on an evolutionary conserved, expressed gene are readily available and have been characterized in some detail. Such an assay would be of great value to human cancer risk assessment and the extrapolation of mutagenicity data between species. It is anticipated that the successful development of this new in vivo model will provide a unique opportunity to study in vivo mutant frequencies in human tissues and cell lines established from human tissues

Phase II

Contract Number: 5R43CA093242-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2002
(last award dollars: 2006)
Phase II Amount
$997,790

Any mutagenesis assay aimed at elucidating the factors leading to an increased incidence of cancer and purporting to play a relevant role in cancer risk assessment should preferably be applicable to several species, i.e. mouse, rat and human. The existence of a cellular pathway with gene(s) that have been evolutionarily conserved from nematodes to man provide the potential to determine mutant frequencies in virtually any organ of any vertebrate species. All parts for the development of an eukaryotic mutagenesis assay based on an evolutionary conserved, expressed gene are readily available and have been characterized in some detail. Such an assay would be of great value to human cancer risk assessment and the extrapolation of mutagenicity data between species. It is anticipated that the successful development of this new in vivo model will provide a unique opportunity to study in vivo mutant frequencies in human tissues and cell lines established from human tissues.

Thesaurus Terms:
cancer risk, cytochrome c, gene expression, model design /development, mutagen testing, technology /technique development DNA damage, reporter gene tissue /cell culture, transfection